Compass Therapeutics, Inc. (CMPX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company's pipeline targets angiogenesis and the immune system, with lead candidates including tovecimig (DLL4 x VEGF-A), CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific), and CTX-10726 (PD-1 x VEGF-A bispecific).
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Licensing Revenue | $0 | $0 | $0 | $850 |
| Net Loss | $(14,259) | $(10,481) | $(50,773) | $(34,342) |
| Net Loss Per Share (Basic/Diluted) | $(0.08) | $(0.08) | $(0.34) | $(0.25) |
| Operating Expenses | $15,817 | $12,239 | $54,849 | $40,901 |
| Interest Income | $1,558 | $1,758 | $4,076 | $5,709 |
| Cash & Cash Equivalents | $46,212 | $19,404 | As of Sept 30, 2025 | |
| Marketable Securities | $173,683 | $83,239 | ||
| Total Liquidity (Cash + Securities) | $219,895 | $219,895 | ||
| Accumulated Deficit | $(415,456) | $(415,456) |
Material Changes vs. Prior Period
- Revenue: No licensing revenue was recognized in Q3 or the nine months ended September 30, 2025, compared to $0.85 million in the prior year period (derived from a milestone payment in 2024).
- Net Loss: Net loss increased by 36% for Q3 2025 ($14.3M) compared to Q3 2024 ($10.5M). For the nine-month period, net loss increased by 48% to $50.8M from $34.3M.
- Operating Expenses: Total operating expenses rose 29% in Q3 and 34% in the nine-month period.
- R&D Expenses: Increased 49% in Q3 ($12.8M vs $8.6M) and 44% in the nine-month period ($42.3M vs $29.3M). The increase is primarily driven by the new candidate CTX-10726 ($4.6M in Q3; $8.0M in 9M) and increased manufacturing costs for tovecimig.
- G&A Expenses: Decreased 18% in Q3 ($3.0M vs $3.6M) due to reduced stock-based compensation, but increased 8% in the nine-month period ($12.6M vs $11.6M) due to market research and commercial preparation costs.
- Liquidity: Cash and marketable securities increased significantly from $126.7M at year-end 2024 to $219.9M at September 30, 2025, following a capital raise.
Guidance, Outlook, and Risks
- Capital Raise: In August 2025, the company completed an underwritten offering of common stock and pre-funded warrants, raising net proceeds of approximately $129.3 million.
- Liquidity Outlook: Management expects current cash resources ($220 million) to fund operating expenses and capital expenditures into 2028.
- Clinical Milestones:
- Tovecimig: Overall survival and progression-free survival data from the Phase 2/3 COMPANION-002 study in Biliary Tract Cancer are expected in late Q1 2026.
- CTX-8371: Phase 1 dose-escalation is complete. A new response was observed in a third indication. Full topline data is expected at a medical meeting in the first half of 2026.
- Risks:
- Regulatory/Political: New Executive Orders (14273 and 14297) issued in April and May 2025 regarding drug pricing and "Most-Favored-Nation" pricing targets pose potential risks to future reimbursement and pricing strategies.
- Development Risk: As a clinical-stage company, there is no assurance that product candidates will obtain regulatory approval or achieve commercial viability.
Investor Verification Checklist
- Cash Runway: Verify the $220 million liquidity position and the specific burn rate assumptions supporting the "into 2028" funding estimate.
- CTX-10726 Costs: Confirm the sustainability of the $8.0 million in R&D spend for this new candidate in the first nine months of 2025.
- Capital Structure: Review the terms of the 6.71 million pre-funded warrants issued in August 2025 and their potential dilution impact upon exercise.
- Regulatory Impact: Assess the potential financial impact of the new 2025 Executive Orders on drug pricing if any product candidate achieves approval.
- Revenue Timeline: Note the absence of revenue in 2025 and the reliance on future milestone payments or commercial sales post-2026.